Skip to main content
SpringerPlus

Table 4 Grade 3 and 4 toxicities [n (%)] associated with NAC, evaluated at cycle 8 a

From: Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival

GROUPS (n = 92)

TOXICITY

NAILS*

HAND-FOOT*

PARESTHESIA

MYALGIA*

FATIGUE

A

6(20.0%)

1 (3.3%)

2 (6.6%)

7 (23.3%)

16 (53.3%)

(n = 30)

B

16 (47.1%)

7 (23.3%)

1 (2.9%)

1 (2.9%)

21 (61.7%)

(n = 34)

C

1 (6.3%)

0 (0%)

2 (12.5%)

1 (6.3%)

9 (56.3%)

(n = 16)

D

8 (66.7%)

1 (8.3%)

2 (16.6%)

0 (0%)

9 (75.0%)

(n = 12)

(A + C)

7 (15.2%)

1 (2.2%)

4 (8.7%)

8 (17.4%)

25 (54.3%)

(n = 46)

(B + D)

24 (52.2%)

8 (17.4%)

3 (6.5%)

1 (2.2%)

30 (65.2%)

(n = 46)

  1. aSerious Adverse Events (SAEs) : n = 13; Suspected Unexpected Serious Adverse Reactions (SUSARs) : n = 1; Deaths : n = 0. NS : Not Significant.
  2. *Statistically significant (Pearson Chi-Square Test). *Nail changes : A v B (χ2 = 5.173, p = 0.023); C v D (χ2 = 11.476, p = 0.007); A + C v B + D (χ2 = 14.060, p = 0.0002). *Hand-foot syndrome : A v B (χ2 = 4.338, p = 0.037); C v D (NS); A + C v B + D (χ2 = 6.035, p = 0.014). Paresthesia : A v B (NS); C v D(NS); A + C v C + D (NS). *Myalgia : A v B (χ2 = 9.572, p = 0.023); A + C v B + D (χ2 = 6.035, p = 0.014). Fatigue : A v B (NS); C v D (NS); A + C v B + D (NS).
Back to article page